Radius Health (RDUS) Receives a Hold from H.C. Wainwright

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Radius Health (RDUS), with a price target of $25.00. The company’s shares closed last Tuesday at $18.62.

According to TipRanks.com, Tsao is a 5-star analyst with an average return of 20.1% and a 57.1% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Crinetics Pharmaceuticals, and Protagonist Therapeutics.

Radius Health has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $23.84 and a one-year low of $10.15. Currently, Radius Health has an average volume of 439.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.